Table of Contents
Leukemia Research and Treatment
Volume 2013 (2013), Article ID 705714, 6 pages
http://dx.doi.org/10.1155/2013/705714
Clinical Study

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy

Department of Hematology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy

Received 16 January 2013; Revised 17 March 2013; Accepted 1 April 2013

Academic Editor: Antonio Cuneo

Copyright © 2013 Chiara Sarlo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Chiara Sarlo, Francesco Buccisano, Luca Maurillo, et al., “Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy,” Leukemia Research and Treatment, vol. 2013, Article ID 705714, 6 pages, 2013. doi:10.1155/2013/705714